AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Managing Tough Real Life Dermatology Cases

Description

In this presentation, Dr. Andrea Maderall, a medical dermatologist, discusses complex dermatology cases, particularly focusing on dermatomyositis and leprosy. The first case involves a 43-year-old woman with amyopathic dermatomyositis who is experiencing a severe flare-up accompanied by ulcerations suggestive of MDA 5 dermatomyositis. Her treatment regimen includes immunosuppressants, but issues with medication adherence are complicating her management. Dr. Maderall emphasizes the importance of identifying cutaneous manifestations and considering treatment adjustments, highlighting rituximab as a potential therapy. The second case pertains to a 50-year-old man diagnosed with tuberculoid leprosy after presenting with an asymptomatic rash and loss of sensory function. The case illustrates the significance of recognizing symptoms and potentially associated risk factors such as armadillo exposure. Dr. Maderall explains the dichotomy of leprosy reactions (type 1 and type 2) that necessitate different treatment strategies, underscoring the challenge of treating immune reactions rather than the infection itself. She concludes with insights on timely diagnosis and appropriate therapy for dermatological conditions, emphasizing the need for awareness of both infectious etiologies and their dermatological manifestations in clinical practice.

View more

Conclusions

  • Amyopathic dermatomyositis patients presenting with MDA5 positivity are at high risk for interstitial lung disease and require careful management due to potential complications.
  • The safety and efficacy of off-label medications for complicated dermatomyositis patients, especially transplant recipients, requires more research.
  • Management strategies for dermatomyositis must consider adherence issues to prescribed therapies.
  • Infectious etiologies should always be considered in immunosuppressed patients, especially when new symptoms arise or when ulcers are observed.
  • Leprosy, particularly in cases without traditional risk factors, is becoming more recognized as endemic in regions such as Central Florida.
  • Treatment for leprosy should include effective multidrug therapy regimens tailored to the patient's specific immunological response.
  • Leprosy patients often experience immunologic reactions, such as Type 1 and Type 2 reactions, which complicate their clinical management.
  • In patients with leprosy, recognizing the signs of immunological reactions is crucial to prevent misdiagnosis as rheumatological conditions.
  • Fiorentino, D., et al. (2011). Dermatopulmonary syndrome: High rates of ILD. J Am Acad Dermatol, 65, 25-34.
  • Vleugels, R. A. Management of refractory cutaneous dermatomyositis in adults. In: UpToDate, Callen J (Ed), Ofori AO (Ed), Wolters Kluwer. (Accessed January 19, 2024).
  • Janeela A, et al. (2024). J Clin Exp Hepatol, 14(2), 101286.
  • Ogawa Y, et al. (2017). Management of ulcers in MDA5. Case Rep Rheumatol, 2017, 5386797.
  • Combalia A, et al. (2018). JAMA Dermatol, 154(3), 371-3.
  • Singh P, et al. (2015). Proc Natl Acad Sci U S A, 112(14), 4459.
  • Franco-Paredes C, et al. (2022). Ther Adv Infect Dis, 9, 20499361221135885.
  • Rodrigues LC, et al. (2011). Lancet Infect Dis, 11(6), 464-70.
  • Bolognia J, et al. (2012). Dermatology. Philadelphia, Elsevier Saunders.
  • Balagon MVF, et al. (2010). Am J Trop Med Hyg, 83(3), 637-44.
  • Khan S, et al. (2023). J Am Acad Dermatol, 88(3), 722-4.
  • Teixeira Junior GJ, et al. (2011). Rev Soc Bras Med Trop, 44, 85-90.